CDKN1B and Miyoshi myopathy: miR-221/222 inhibitors triggered in vitro anti-proliferative effects and up-regulation of canonic miR-221/222 targets, including p27Kip1, PUMA, PTEN, and p57Kip2, in MM cells highly expressing miR-221/222.